# VRD GmbH

> VRD GmbH is a VC fund in Heidelberg backing Food and Beverage and Fitness. See 10 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Heidelberg, Germany
- Total investments: 10
- Last investment: Jul 2023
- Lead investor: 30%
- Last updated: Aug 2026
- Website: http://vrd-investment.com/

VRD GmbH is a VC fund in Heidelberg focused on Food and Beverage and Fitness. They are the family office of a traditional family business.

## Contacts

5 contacts available for VRD GmbH. Shizune tracks 1 team members at VRD GmbH. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/vrd-gmbh-2?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $5.9M–$11M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Food and Beverage | 2 | 20% |
| Fitness | 1 | 10% |
| E-Commerce | 1 | 10% |
| Health Care | 1 | 10% |
| Biotechnology | 1 | 10% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 30% |
| Funding Round | 2 | 20% |
| Series A | 1 | 10% |
| Series H | 1 | 10% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Germany | 2 | 20% |
| Australia | 1 | 10% |
| United Kingdom | 1 | 10% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Abe Abe Gong | Co-Founder & CEO | 0 | https://shizune.co/investors/profile/abe-abe-gong |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| SUSHI Bikes | SUSHI Bikes has developed the perfect e-bike for modern urban people. |  |  | Jul 12, 2023 |  |
| SUSHI Bikes | SUSHI Bikes has developed the perfect e-bike for modern urban people. |  | Seed | Jul 12, 2023 |  |
| Mighty Pea | Mighty Pea is a pea milk producer, which uses yellow split peas in the creation of its beverages. | $5.9M | Seed | Dec 08, 2021 |  |
| Lyre's Spirit Co | Many years in the making, Lyre’s exquisite range of lovingly crafted alcohol-free, classic spirits was borne from a quest to make the impossible possible. To provide an alternative to those who don’t wish to imbibe alcohol, but still wish to enjoy the mirth, merriment and social intercourse of an evening soiree or shindig. But this is not justany alternative. Every Lyre’s spirit looks, tastes and sashays around the palate just like the original. And yet, the absence of giggle juice enables revellers to remain clear-headed, of good cheer and in fine fettle to pursue whatever tickles their fancy the following day. Lyre’s – the finest range of non-alcoholic classic spirits the world has ever seen. | $26.8M | Series A | Nov 15, 2021 |  |
| Lyre's Spirit Co | Many years in the making, Lyre’s exquisite range of lovingly crafted alcohol-free, classic spirits was borne from a quest to make the impossible possible. To provide an alternative to those who don’t wish to imbibe alcohol, but still wish to enjoy the mirth, merriment and social intercourse of an evening soiree or shindig. But this is not justany alternative. Every Lyre’s spirit looks, tastes and sashays around the palate just like the original. And yet, the absence of giggle juice enables revellers to remain clear-headed, of good cheer and in fine fettle to pursue whatever tickles their fancy the following day. Lyre’s – the finest range of non-alcoholic classic spirits the world has ever seen. | $6.9M | Seed | May 04, 2021 |  |
| Lyre's Spirit Co | Many years in the making, Lyre’s exquisite range of lovingly crafted alcohol-free, classic spirits was borne from a quest to make the impossible possible. To provide an alternative to those who don’t wish to imbibe alcohol, but still wish to enjoy the mirth, merriment and social intercourse of an evening soiree or shindig. But this is not justany alternative. Every Lyre’s spirit looks, tastes and sashays around the palate just like the original. And yet, the absence of giggle juice enables revellers to remain clear-headed, of good cheer and in fine fettle to pursue whatever tickles their fancy the following day. Lyre’s – the finest range of non-alcoholic classic spirits the world has ever seen. | $9M | Seed | May 01, 2021 |  |
| Lyre's Spirit Co | Many years in the making, Lyre’s exquisite range of lovingly crafted alcohol-free, classic spirits was borne from a quest to make the impossible possible. To provide an alternative to those who don’t wish to imbibe alcohol, but still wish to enjoy the mirth, merriment and social intercourse of an evening soiree or shindig. But this is not justany alternative. Every Lyre’s spirit looks, tastes and sashays around the palate just like the original. And yet, the absence of giggle juice enables revellers to remain clear-headed, of good cheer and in fine fettle to pursue whatever tickles their fancy the following day. Lyre’s – the finest range of non-alcoholic classic spirits the world has ever seen. | $11.2M | Seed | Sep 25, 2020 |  |
| Lophius Biosciences | Lophius Biosciences is a young biotechnology company developing innovative products for the diagnosis of acute infectious and autoimmune diseases. The company is also offering custom-made services in the area of cell based bioactivity and quality tests for pharmaceutical agents. The core competencies of Lophius Biosciences are in the area ofImmunology and T-cell diagnostics.Lophius Biosciences is a privately-held German biotechnology company focusing on the development and marketing of innovative immune diagnostic systems to improve therapy control and personalized treatment of patients in the area of transplantation, infectious and autoimmune diseases.The company’s developments are based on its expertise in cell-mediated immunity as well as on its proprietary T-activation® and Reverse T Cell Technology platforms. Whereas the T-activation® technology platform allows an efficient stimulation of a broad spectrum of clinically-relevant immune effector cells to accurately measure the cell-mediated immunity, the Reverse T Cell Technology platform can distinguish between active and memory T cells to develop innovative diagnostics. | $2.4M | Series H | Mar 18, 2017 |  |
| Lophius Biosciences | Lophius Biosciences is a young biotechnology company developing innovative products for the diagnosis of acute infectious and autoimmune diseases. The company is also offering custom-made services in the area of cell based bioactivity and quality tests for pharmaceutical agents. The core competencies of Lophius Biosciences are in the area ofImmunology and T-cell diagnostics.Lophius Biosciences is a privately-held German biotechnology company focusing on the development and marketing of innovative immune diagnostic systems to improve therapy control and personalized treatment of patients in the area of transplantation, infectious and autoimmune diseases.The company’s developments are based on its expertise in cell-mediated immunity as well as on its proprietary T-activation® and Reverse T Cell Technology platforms. Whereas the T-activation® technology platform allows an efficient stimulation of a broad spectrum of clinically-relevant immune effector cells to accurately measure the cell-mediated immunity, the Reverse T Cell Technology platform can distinguish between active and memory T cells to develop innovative diagnostics. | $4.7M | Series H | Jul 26, 2016 |  |
| Lophius Biosciences | Lophius Biosciences is a young biotechnology company developing innovative products for the diagnosis of acute infectious and autoimmune diseases. The company is also offering custom-made services in the area of cell based bioactivity and quality tests for pharmaceutical agents. The core competencies of Lophius Biosciences are in the area ofImmunology and T-cell diagnostics.Lophius Biosciences is a privately-held German biotechnology company focusing on the development and marketing of innovative immune diagnostic systems to improve therapy control and personalized treatment of patients in the area of transplantation, infectious and autoimmune diseases.The company’s developments are based on its expertise in cell-mediated immunity as well as on its proprietary T-activation® and Reverse T Cell Technology platforms. Whereas the T-activation® technology platform allows an efficient stimulation of a broad spectrum of clinically-relevant immune effector cells to accurately measure the cell-mediated immunity, the Reverse T Cell Technology platform can distinguish between active and memory T cells to develop innovative diagnostics. | $2.2M |  | May 08, 2014 |  |

10 of 10 investments shown.

## Co-investors
- [Maropost Ventures](https://shizune.co/investors/profile/maropost-ventures) — VC Fund, 5 deals together
- [DLF Venture](https://shizune.co/investors/profile/dlf-venture) — VC Fund, 4 deals together
- [Döhler Ventures](https://shizune.co/investors/profile/doehler-ventures) — VC Fund, 4 deals together
- [Bitburger Ventures](https://shizune.co/investors/profile/bitburger-ventures) — VC Fund, 3 deals together
- [Morgan Creek Capital Management](https://shizune.co/investors/profile/morgan-creek-capital-management) — VC Fund, 3 deals together
- [BayBG Venture Capital](https://shizune.co/investors/profile/baybg) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Artesian VC](https://shizune.co/investors/profile/artesian-capital-management) — VC Fund
- [Blackbird Ventures](https://shizune.co/investors/profile/blackbird-ventures-australia) — VC Fund

## Featured in investor lists
- [Gaming Investors in Australia](https://shizune.co/investors/gaming-investors-australia)
- [Gaming VC Funds in Australia](https://shizune.co/investors/gaming-vc-funds-australia)
- [Food and Beverage Investors in Australia](https://shizune.co/investors/food-and-beverage-investors-australia)
- [Food and Beverage VC Funds in Australia](https://shizune.co/investors/food-and-beverage-vc-funds-australia)
- [Food and Beverage Investors in Oceania](https://shizune.co/investors/food-and-beverage-investors-oceania)
- [Food and Beverage VC Funds in Oceania](https://shizune.co/investors/food-and-beverage-vc-funds-oceania)

## FAQ

### What does VRD GmbH invest in?

VRD GmbH invests primarily in Food and Beverage, Fitness and E-Commerce startups, most often at Seed and Funding Round stage. Most of the 10 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is VRD GmbH's check size?

VRD GmbH typically joins rounds of $5.9M–$11M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds VRD GmbH participates in.

### How do I contact VRD GmbH?

Public channels for VRD GmbH include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at VRD GmbH?

The team at VRD GmbH includes Abe Abe Gong (Co-Founder & CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co